Mobile

Assessment of the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab

Update Il y a 4 ans
Reference: EUCTR2011-002510-36

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Efficacy of intravenous administration of secukinumab compared with subcutaneous administration of secukinumab with respect to both PASI 75 and IGA 0 or 1 response

Inclusion criteria

  • Moderate to severe chronic plaque-type psoriasis

Links